Question explored with the scientific record
Amlodopine
Amlodipine lowers blood pressure and has some evidence for organ protection, but the safety data is thin and the side effects are real.
The evidence here is a mix of small human trials and animal studies, nearly all funded or conducted by the manufacturers of the drugs being tested. The 2014 study comparing lercanidipine to amlodipine in stroke patients found that while both drugs lowered blood pressure similarly, amlodipine caused 19.2% adverse events compared to 5.7% for lercanidipine [1]. That is a threefold higher rate of side effects, mostly edema (swelling). The 2008 ATAR study found that adding ramipril to amlodipine cut the edema rate from 18.7% to 7.6%, but the combination still had a 22.1% overall adverse event rate [6]. The 2017 safety review of the perindopril-amlodipine combination reported an 8.6% rate of pedal edema across all trials [5], which is not trivial.
The animal data is more interesting. In rats with pulmonary hypertension, amlodipine improved survival from 43% to 77% and dramatically reduced pulmonary artery pressure [2]. In stroke-prone hypertensive rats, combining amlodipine with candesartan lowered blood pressure from 236 mmHg to 155 mmHg and reduced heart weight [3]. These are real effects, but they are in rats, not humans.
What is missing from this retrieval is long-term safety data. No study here follows patients for more than a few months. No study compares amlodipine to a true placebo in a large, modern trial with hard endpoints like heart attack or death. The 1990 study in elderly patients found that amlodipine stays in the body much longer in older people (half-life 58 hours vs 42 hours in the young) [4], which means dosing needs to be careful, but no study here tests what that means for falls, kidney function, or cognitive effects over years.
My call: amlodipine works for blood pressure and has some evidence for organ protection, but the side effect burden is real and the long-term safety data is absent. Confidence: moderate.
Sources used 6
-
Effects of lercanidipine versus amlodipine in hypertensive patients with cerebral ischemic stroke
This study compares the efficacy and safety of lercanidipine and amlodipine in treating hypertensive patients with acute cerebral ischemic stroke, finding that both drugs effectively reduce blood pressure but lercanidipine has a better safety profile.
DOI: 10.1185/03007995.2014.964855 -
AMLODIPINE PREVENTS MONOCROTALINE‐INDUCED PULMONARY ARTERIAL HYPERTENSION AND PROLONGS SURVIVAL IN RATS INDEPENDENT OF BLOOD PRESSURE LOWERING
The study investigates the effects of amlodipine on preventing and reversing monocrotaline-induced pulmonary arterial hypertension in rats, demonstrating that it significantly improves survival and inhibits pulmonary vascular remodeling independent of blood pressure reduction.
DOI: 10.1111/j.1440-1681.2007.04618.x -
Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats
This study investigates the vascular protective effects of candesartan and amlodipine combination therapy compared to monotherapy in stroke-prone spontaneously hypertensive rats, demonstrating significant reductions in blood pressure and oxidative stress.
DOI: 10.1038/hr.2010.224 -
Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: Pharmacodynamics in relation to disposition
This study investigates the pharmacodynamics and disposition of amlodipine, a calcium antagonist, in elderly versus young hypertensive patients, revealing that elderly patients experience prolonged drug elimination and greater blood pressure reduction at equivalent plasma concen…
DOI: 10.1038/clpt.1990.120 -
Perindopril arginine and amlodipine besylate for hypertension: a safety evaluation
A comprehensive safety evaluation of the fixed-dose combination perindopril arginine and amlodipine besylate for hypertension, synthesizing six randomized trials and numerous observational studies to conclude that its safety profile largely mirrors its individual components, wit…
DOI: 10.1080/14740338.2018.1397129 -
An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: The assessment of combination therapy of amlodipine/ramipril (ATAR) study
This study evaluates the efficacy and tolerability of a fixed-dose combination of amlodipine and ramipril compared to amlodipine monotherapy in patients with essential hypertension over an 18-week period, finding that the combination therapy significantly reduces blood pressure …
DOI: 10.1016/j.clinthera.2008.09.008